

New Glycosides from *Cistanche salsa*

by Li Lei^a), Yong Jiang^a), Xiao-Ming Liu^a), Peng-Fei Tu^{*a}), Li-Jun Wu^b), and Fa-Kui Chen^b)

^a) Department of Natural Medicine, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100083, P. R. China

(phone/fax: +86-10-82802750; e-mail: pengfeitu@bjmu.edu.cn)


^b) School of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, P. R. China

Six new glycosides, salsasides A–F (**1–6**, resp.), were isolated from the stems of *Cistanche salsa*, together with seven known glycosidic compounds. Their structures were elucidated by means of ester hydrolysis and chemical derivatization, in-depth NMR spectroscopic and mass spectrometric analyses, and by comparison with literature data of related compounds. The new glycosides are based on β -D-glucose (Glc) and α -L-rhamnose (Rha), carrying acetyl (Ac), benzyl (Bn), phenethyl, coumaroyl (Cou), and caffeoyl (Caf) substituents.

Introduction. – *Cistanche salsa* (C. A. MEY.) G. BECK, one of the species of *Herba Cistanche*, is a short parasitic Orobanchaceae plant native to Northwest China. As an important tonic in traditional Chinese medicine (TCM), the stems of *Herba Cistanche* have long been used by the Chinese and Japanese against kidney deficiency, female infertility, morbid leucorrhea, neurasthenin, and senile constipation due to colonic inertia, etc. [1]. Just as in other *Cistanche* plants, phenethyl-based glycosides are the main active constituents of *C. salsa*. These compounds were reported to have neuroprotective activity against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice [2–4]. There are only few phytochemical studies concerning *C. salsa*, the first ones dating back ca. 20 years [5–8]. In 1995, Moriya *et al.* [9][10] reported that the plant material of *C. salsa* had been identified falsely, when he investigated the sources of *Herba Cistanche* from a Japanese medical market [9][10]. Therefore, it is necessary to re-investigate the chemical constituents of *C. salsa*.

In the present work on *C. salsa*, we report the isolation and structure elucidation of six new glycosides, salsasides A–F (**1–6**), with different substituents, including acetyl (Ac), benzyl (Bn), caffeoyl (Caf), and coumaroyl (Cou) residues. Also isolated from the same extract were the following seven known glycosides: tubuloside B [11], acteoside [6], isoacteoside [11], 2'-acetylacteoside [7], echinacoside [6], cistanoside C [7], and cistanoside D [7].

Results and Discussion. – Compound **1** was isolated as an amorphous powder, and its molecular formula was deduced as C₂₈H₃₄O₁₃ by HR-ESI-MS (m/z 596.2348 ($[M + NH_4]^+$; calc. 596.2343). The ¹H-NMR data of **1** (Table 1) exhibited characteristic signals of an (*E*)-configured caffeoyl (Caf) group, with *ABX*-type aromatic signals at δ (H) 7.07 (br. *s*), 6.76 (br. *d*, $J=8.5$ Hz), and 7.03 (*d*, $J=8.5$ Hz), two olefinic H-



atoms at $\delta(\text{H})$ 7.51 ($d, J = 16.0$) and 6.34 ($d, J = 16.0$ Hz), and a Bn moiety with five aromatic resonances and two nonequivalent H-atoms at $\delta(\text{H})$ 4.59, 4.77 ($2d, J = 12.0$ Hz each), which suggested that **1** was a Bn-substituted compound [12].

Total acid hydrolysis of **1** afforded rhamnose (Rha) and glucose (Glc). The NMR-data of **1** were similar to those of tubuloside B [11], except that the signals of a 3,4-dihydroxyphenylethanol unit were replaced by those of a Bn group. In the HMBC spectrum of **1**, correlations between the two nonequivalent H-atoms at $\delta(\text{H})$ 4.59, 4.77 ($\alpha\text{-CH}_2$ of aglycone) and $\delta(\text{C})$ 101.7 (C(1') of Glc), of both $\delta(\text{H})$ 4.40 (br. $d, J = 11.5$ Hz, 1 H of $\text{CH}_2(6')$) and 4.23 (m , 1 H of $\text{CH}_2(6')$) with $\delta(\text{C})$ 166.6 (C(α') of ester), and of $\delta(\text{H})$ 5.04 (br. s , H-C(1'')) and $\delta(\text{C})$ 80.8 (C(3')) established the linkages between the aglycone, ester, and sugar moieties.

On the basis of the above spectroscopic evidence, in combination with 2D-NMR data, the structure of **1** was elucidated as benzyl 6-*O*-[(*E*)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-3-*O*- α -L-rhamnopyranosyl- β -D-glucopyranoside¹⁾, and named *salsaside A*.

Compound **2** was isolated as an amorphous powder, and its molecular formula was determined as $\text{C}_{28}\text{H}_{34}\text{O}_{13}$ by HR-ESI-MS (m/z 596.2345 ($[M + \text{NH}_4]^+$)). The only difference between **1** and **2** was that the Caf moiety was attached at 4'-position in **2** instead at 6'-position. This was evident in the HMBC spectrum of **2**, where the signal at $\delta(\text{H})$ 4.96 ($t, J = 9.0$ Hz, H-C(4')) was correlated with $\delta(\text{C})$ 167.3 (C=O of Caf), and further corroborated by comparison with the NMR data of 2'-acetylacteoside [4]. Thus, compound **2** was identified as benzyl 4-*O*-[(*E*)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-3-*O*- α -L-rhamnopyranosyl- β -D-glucopyranoside, and named *salsaside B*.

Salsaside C (**3**) was isolated as an amorphous powder, and its molecular formula was elucidated as $\text{C}_{28}\text{H}_{34}\text{O}_{12}$ by HR-ESI-MS (m/z 561.1958 ($[M - \text{H}]^-$; calc. 561.1972)). The NMR data of **3** were similar to those of **2**, except that the signals of the Caf group were replaced by those of an (*E/Z*)-coumaroyl (Cou) moiety (see

¹⁾ Rhamnopyranose corresponds to 6-deoxymannopyranose.

Table 1. NMR Data of Compounds 1–3. At 500/125 MHz, resp., in (D₆)DMSO (1, 3) and CD₃OD (2); δ in ppm, J in Hz. Arbitrary atom numbering. Assignments are based on COSY, HMBC, and HMQC experiments.

Atom	1		2		3 ^{a)}	
	δ (C)	δ (H)	δ (C)	δ (H)	δ (C)	δ (H)
C(1)	137.7	–	138.0	–	139.0	–
H–C(2,6)	127.8	7.37 (br. <i>d</i> , $J=7.5$)	128.2	7.45 (br. <i>d</i> , $J=7.5$)	129.2	7.42 (br. <i>d</i> , $J=7.5$)
H–C(3,5)	128.1	7.32 (br. <i>t</i> , $J=7.5$)	128.3	7.36 (br. <i>t</i> , $J=7.5$)	129.3	7.36 (br. <i>t</i> , $J=7.5$)
H–C (4)	127.5	7.27 (br. <i>t</i> , $J=7.5$)	127.8	7.31 (br. <i>t</i> , $J=7.5$)	128.7	7.29 (br. <i>t</i> , $J=7.5$)
α -CH ₂	69.7	4.59 (<i>d</i> , $J=12.0$), 4.77 (<i>d</i> , $J=12.0$)	71.0	4.71 (<i>d</i> , $J=12.0$), 4.98 (<i>d</i> , $J=12.0$)	71.9	4.62 (<i>d</i> , $J=11.5$), 4.87 (<i>d</i> , $J=11.5$)
H–C(1')	101.7	4.32 (<i>d</i> , $J=7.5$)	102.2	4.47 (<i>d</i> , $J=8.0$)	103.2	4.42 (<i>d</i> , $J=8.0$), 4.40 (<i>d</i> , $J=7.5$)
H–C(2')	74.1	3.20 (<i>t</i> , $J=9.5$)	75.2	3.49 (<i>t</i> , $J=9.0$)	76.2	3.46 (<i>t</i> , $J=8.5$)
H–C(3')	80.8	3.40 (<i>t</i> , $J=9.5$)	80.7	3.84 (<i>t</i> , $J=9.0$)	80.8	3.81 (<i>t</i> , $J=9.0$)
H–C(4')	68.6	3.23 (<i>t</i> , $J=9.5$)	69.7	4.96 (<i>t</i> , $J=9.0$)	70.6	4.75 (<i>t</i> , $J=9.5$), 4.71 (<i>t</i> , $J=9.5$)
H–C(5')	73.8	3.46–3.50	75.1	3.57–3.59	76.1	3.47–3.51
CH ₂ (6')	63.4	4.40 (br. <i>d</i> , $J=11.5$), 4.21–4.25	61.4	3.67 (br. <i>d</i> , $J=10.0$), 3.57–3.61	62.4	3.39–3.43, 3.26–3.30
H–C(1'')	100.6	5.04 (br. <i>s</i>)	102.1	5.21 (br. <i>s</i>)	103.1	5.02 (br. <i>s</i>)
H–C(2'')	70.6	3.69 (br. <i>s</i>)	71.3	3.94 (<i>d</i> , $J=2.0$)	72.3	3.68 (br. <i>s</i>)
H–C(3'')	70.6	3.46–3.54	71.1	3.57–3.61	72.0	3.30 (<i>dd</i> , $J=9.0, 3.0$)
H–C(4'')	72.1	3.18 (<i>t</i> , $J=9.5$)	72.8	3.32 (<i>t</i> , $J=9.5$)	73.8	3.09 (<i>t</i> , $J=9.5$)
H–C(5'')	68.1	3.89–3.01	69.4	3.57–3.61	70.4	3.40–3.45
Me(6'')	17.8	1.09 (<i>d</i> , $J=6.5$)	17.5	1.11 (<i>d</i> , $J=6.0$)	18.3	0.94 (<i>d</i> , $J=6.5$), 1.03 (<i>d</i> , $J=6.0$)
C(1''')	125.5	–	126.7	–	127.1, 130.0	–
H–C(2''')	114.9	7.07 (br. <i>s</i>)	114.2	7.08 (<i>d</i> , $J=1.5$)	131.4, 134.3	7.53 (<i>d</i> , $J=9.0$), 7.70 (<i>d</i> , $J=9.0$)
C(3''')	145.6	–	145.8	–	116.8, 115.8	6.80 (<i>d</i> , $J=9.0$), 6.75 (<i>d</i> , $J=9.0$)
C(4''')	148.4	–	148.8	–	161.5, 160.4	–
H–C(5''')	115.7	6.76 (br. <i>d</i> , $J=8.5$)	115.5	6.81 (<i>d</i> , $J=8.0$)	116.8, 115.8	6.80 (<i>d</i> , $J=9.0$), 6.75 (<i>d</i> , $J=9.0$)
H–C(6''')	121.4	7.03 (<i>d</i> , $J=8.5$)	122.2	6.98 (<i>dd</i> , $J=8.0, 1.5$)	131.4, 134.3	7.53 (<i>d</i> , $J=9.0$), 7.70 (<i>d</i> , $J=9.0$)
C=O	166.6	–	167.3	–	168.3, 166.0	–
α' -C(H)=	113.9	6.34 (<i>d</i> , $J=16.0$)	113.7	6.31 (<i>d</i> , $J=16.0$)	114.7, 113.8	6.34 (<i>d</i> , $J=15.5$), 5.70 (<i>d</i> , $J=12.5$)
β' -C(H)=	145.3	7.51 (<i>d</i> , $J=16.0$)	147.0	7.62 (<i>d</i> , $J=16.0$)	147.6	7.55 (<i>d</i> , $J=15.5$), 6.92 (<i>d</i> , $J=12.5$)

^{a)} Partly doubled signals due to (*E/Z*) mixture (see text).

Table 1). The presence of an (*E/Z*)-mixture was indicated by split (2.38:1) NMR resonances as well as by peak doubling in the HPLC chromatogram, a phenomenon reported before in some phenethyl glycosides [13][14]. In the HMBC spectrum of 3, correlations between the two nonequivalent aglycone α -CH₂ resonances at δ (H)

4.62, 4.87 (*2d*, $J=11.5$ Hz each) and $\delta(\text{C})$ 103.2 (C(1')), between $\delta(\text{H})$ 4.75/4.71 (*t*, $J=7.5$ Hz, H–C(4')) and $\delta(\text{C})$ 168.3/166.0 (C=O of Cou), and between $\delta(\text{H})$ 5.02 (*br. s.*, H–C(1'')) and $\delta(\text{C})$ 80.8 (C(3')) established the linkages between the aglycone, the ester, and the sugar moieties. Thus, the structure of compound **3** was elucidated as benzyl 4-*O*-[(*E/Z*)-3-(4-hydroxyphenyl)prop-2-enoyl]-3-*O*- α -L-rhamnopyranosyl- β -D-glucopyranoside, and named *salsaside C*.

Salsaside D (**4**) was obtained as an amorphous powder, and its molecular formula was determined as C₃₁H₃₈O₁₅ by HR-ESI-MS (m/z 668.2563 ($[M+\text{NH}_4]^+$; calc. 668.2554). The ¹H-NMR spectrum of **4** (Table 2) exhibited signals characteristic of an (*E*)-Caf group and of a (4-hydroxyphenyl)ethoxy group [$\delta(\text{H})$ 2.65 (*m*, 2 H), 3.55 (*m*, 1 H), 3.90 (*m*, 1 H), 6.64 (*d*, $J=8.0$ Hz, 2 H), 6.97 (*d*, $J=8.0$ Hz, 2 H)]. Total acid hydrolysis of **4** afforded Rha and Glc. The fragment ion peak observed in the negative FAB mass spectrum at m/z 43, and the NMR signals at $\delta(\text{H})$ 1.95 (*s*, 3 H), and at $\delta(\text{C})$ 169.3 and 20.7, indicated the presence of an Ac group. The ¹H- and ¹³C-NMR data were very similar to those of syringalide A 3'- α -L-rhamnopyranoside, except for an additional Ac signal [15]. In the HMBC spectrum of **4**, the signal at $\delta(\text{H})$ 4.68 (*t*, $J=9.0$ Hz, H–C(2')) was correlated with $\delta(\text{C})$ 169.3 (C=O of Ac), which indicated that the Ac moiety was linked to C(2) of Glc. Thus, the structure of compound **4** was elucidated as 2-(4-hydroxyphenyl)ethyl 2-*O*-acetyl-4-*O*-[(*E*)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-3-*O*- α -L-rhamnopyranosyl- β -D-glucopyranoside, and named *salsaside D*.

Compound **5** was isolated as an amorphous powder, and its molecular formula was determined as C₃₂H₄₀O₁₆ by HR-ESI-MS (m/z 679.2228 ($[M-\text{H}]^-$; calc. 679.2238). The ¹H- and ¹³C-NMR data of **5** (Table 2) were very similar to those of **4**, except for the signals of the phenethyl moiety. In the ¹H-NMR spectrum of **5**, there was an *AMX* system [$\delta(\text{H})$ 6.63 (*d*, $J=8.0$ Hz, 1 H), 6.69 (*d*, $J=8.0$ Hz, 1 H), 6.77 (*br. s.*, 1 H)] and a MeO signal at $\delta(\text{H})$ 3.85 (*s*, 3 H). In the HMBC spectrum, the MeO signal was correlated with $\delta(\text{C})$ 148.7 (C(3)), which, in turn, correlated with $\delta(\text{H})$ 6.69 (*d*, $J=8.0$ Hz, H–C(5)) and 6.77 (*br. s.*, H–C(2)). Therefore, the MeO substituent was at C(3) of the phenethyl moiety, as corroborated by comparison with literature data [7]. Hence, the structure of compound **5** was elucidated as 2-(4-hydroxy-3-methoxyphenyl)ethyl 2-*O*-acetyl-4-*O*-[(*E*)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-3-*O*- α -L-rhamnopyranosyl- β -D-glucopyranoside, and named *salsaside E*.

Compound **6** was isolated as an amorphous powder, and its molecular formula was determined as C₃₁H₃₈O₁₅ by HR-ESI-MS (m/z 668.2543 ($[M+\text{NH}_4]^+$; calc. 668.2554)). The ¹H-NMR spectrum of **6** exhibited signals characteristic of an (*E*)-Cou group [$\delta(\text{H})$ 6.35 and 7.46 (*2d*, $J=16.0$ Hz each, 1 H each), 6.69 (*d*, $J=7.5$ Hz, 2 H), 7.45 (*d*, $J=7.5$ Hz, 2 H)], of a (3,4-dihydroxyphenyl)ethoxy moiety [$\delta(\text{H})$ 6.31 (*br. d*, $J=8.0$ Hz, 1 H), 6.46 (*br. s.*, 1 H), 6.49 (*br. d*, $J=8.0$ Hz, 1 H), 2.49 (*m*, CH₂), 3.41 and 3.72 (*2m*, 1 H each)], and of two anomeric resonances [$\delta(\text{H})$ 4.45 (*d*, $J=8.5$ Hz, H–C(1')), 4.55 (*br. s.*, H–C(1''))]. Like in **4** and **5**, there was also an AcO group present in **6** [$\delta(\text{H})$ 1.88 (*s*, 3 H); $\delta(\text{C})$ 169.2, 20.6], which was at C(2') of the Glc moiety, as determined by HMBC experiments. In the HMBC spectrum, correlations were observed between the signals of CH₂(6') and $\delta(\text{C})$ 166.6 (C=O of Cou), between $\delta(\text{H})$ 3.41, 3.72 (*2m*, α -CH₂ of aglycone) and $\delta(\text{C})$ 99.5 (C(1')), and between $\delta(\text{H})$ 4.55 (*br. s.*, H–C(1'')) and $\delta(\text{C})$ 68.8 (C(3')), from which all linkages were established. Thus, the structure of compound **6** was settled as 2-(3,4-dihydroxyphenyl)ethyl 2-*O*-acetyl-6-*O*-[(*E*)-3-(4-

Table 2. NMR Data of Compounds 4–6. At 500/125 MHz, resp., in (D₆)DMSO (4, 6) and CD₃OD (5); δ in ppm, J in Hz. Arbitrary atom numbering. Assignments are based on COSY, HMBC, and HMQC experiments.

Atom	4		5		6	
	δ (C)	δ (H)	δ (C)	δ (H)	δ (C)	δ (H)
C(1)	128.9	–	131.8	–	129.3	–
H–C(2)	129.9	6.97 (<i>d</i> , $J=8.0$)	113.9	6.77 (br. <i>s</i>)	116.3	6.46 (br. <i>s</i>)
H–C(3)	115.1	6.64 (<i>d</i> , $J=8.0$)	148.7	–	145.0	–
H–C(4)	155.7	–	145.8	–	143.6	–
H–C(5)	115.1	6.64 (<i>d</i> , $J=8.0$)	116.0	6.69 (<i>d</i> , $J=8.0$)	115.4	6.49 (br. <i>d</i> , $J=8.0$)
H–C(6)	129.9	6.97 (<i>d</i> , $J=8.0$)	122.3	6.63 (<i>d</i> , $J=8.0$)	119.5	6.31 (br. <i>d</i> , $J=8.0$)
α -CH ₂	70.0	3.51–3.59, 3.89–3.92	71.9	4.08–4.12, 3.50–3.54	69.9	3.39–3.43, 3.69–3.73
β -CH ₂	34.5	2.64–2.66	36.6	2.74–2.78	34.8	2.44–2.51
3-MeO	–	–	56.3	3.85 (<i>s</i>)	–	–
H–C(1')	99.3	4.60 (<i>d</i> , $J=7.5$)	101.8	4.53 (<i>d</i> , $J=8.0$)	99.5	4.45 (<i>d</i> , $J=8.5$)
H–C(2')	73.6	4.68 (<i>t</i> , $J=9.0$)	75.1	4.84 (<i>t</i> , $J=9.0$)	73.3	4.55 (<i>t</i> , $J=9.0$)
H–C(3')	78.2	3.95 (<i>t</i> , $J=9.5$)	80.5	4.00 (<i>t</i> , $J=9.0$)	79.5	3.52 (<i>t</i> , $J=9.0$)
H–C(4')	69.0	4.80 (<i>t</i> , $J=9.5$)	70.6	4.98 (<i>t</i> , $J=9.0$)	68.8	3.25 (<i>t</i> , $J=9.0$)
H–C(5')	74.6	3.51–3.68	76.1	3.56–3.62	73.8	3.45–3.49
CH ₂ (6')	60.5	3.31–3.35 3.36–3.42	62.2	3.60–3.64 3.51–3.55	63.1	4.29 (<i>d</i> , $J=11.5$) 4.10–4.15
MeCO	20.7	1.95 (<i>s</i>)	20.8	1.92 (<i>s</i>)	20.6	1.88 (<i>s</i>)
MeCO	169.3	–	171.3	–	169.2	–
H–C(1'')	102.1	4.59 (br. <i>s</i>)	103.3	4.79 (<i>s</i>)	101.3	4.55 (br. <i>s</i>)
H–C(2'')	70.9	3.35 (br. <i>s</i>)	72.6	3.60–3.68	70.5	3.29 (br. <i>s</i>)
H–C(3'')	70.2	3.20 (br. <i>d</i> , $J=10.0$)	71.9	3.60–3.68	70.7	3.39 (br. <i>d</i> , $J=10.5$)
H–C(4'')	71.5	3.06 (<i>t</i> , $J=9.5$)	73.6	3.25 (<i>t</i> , $J=9.5$)	71.9	3.08 (<i>t</i> , $J=9.0$)
H–C(5'')	69.4	3.26–3.34	70.8	3.53 (br. <i>d</i>)	68.7	3.67–3.72
Me(6'')	18.3	0.90 (<i>d</i> , $J=6.0$)	18.5	1.06 (<i>d</i> , $J=6.0$)	17.8	1.00 (<i>d</i> , $J=6.0$)
C(1''')	125.5	–	127.6	–	125.1	–
H–C(2''')	114.7	7.02 (br. <i>s</i>)	115.2	7.03 (br. <i>s</i>)	130.4	7.45 (<i>d</i> , $J=7.5$)
C(3''')	145.7	–	146.7	–	115.8	6.69 (<i>d</i> , $J=7.5$)
C(4''')	148.8	–	149.6	–	160.0	–
H–C(5''')	115.9	6.75 (<i>d</i> , $J=7.0$)	116.5	6.77 (br. <i>d</i> , $J=7.5$)	115.8	6.69 (<i>d</i> , $J=7.5$)
H–C(6''')	121.7	6.96 (<i>d</i> , $J=7.0$)	123.2	6.94 (br. <i>d</i> , $J=7.5$)	130.4	7.45 (<i>d</i> , $J=7.5$)
COO	165.8	–	168.1	–	166.6	–
α' -CH=	113.4	6.21 (<i>d</i> , $J=16.0$)	114.5	6.26 (<i>d</i> , $J=16.0$)	114.0	6.35 (<i>d</i> , $J=16.0$)
β' -CH=	146.1	7.46 (<i>d</i> , $J=16.0$)	148.2	7.59 (<i>d</i> , $J=16.0$)	145.0	7.46 (<i>d</i> , $J=16.0$)

hydroxyphenyl)prop-2-enoyl]-3-*O*- α -L-rhamnopyranosyl- β -D-glucopyranoside, and named *salsaside F*.

In compounds 1–6, the configuration at the anomeric center of the Glc residue was deduced to be β from J values of 7.5–8.5 Hz. In the case of the Rha residues, the α -anomeric configuration was derived by comparison of the pertinent ¹³C-NMR data with those given in the literature [6]. The absolute configurations of the sugars, D-Glc and L-Rha, were determined by GC analysis of chiral derivatives (see *Exper. Part*) in comparison with standard monosaccharides [16].

This study was financially supported by the National Natural Science Funds of China (No. 30070887). We kindly acknowledge Dr. *Haiming Shi* for help during manuscript preparation.

Experimental Part

General. Silica gel (200–300 mesh; *Qing Dao Hai Yang Chemical Group, Co.*), *Sephadex LH-20* (*Pharmacia*), *D101* resin (*Tianjin Chemical, Co.*), and *ODS* (100–200 mesh; *Fuji Sylisia Chemical, Ltd.*) were used for column chromatography (CC). Prep. HPLC was performed on a *Waters-600* instrument, using an *RP-C₁₈* column (10×250 mm i.d.; *Alltech*) at a flow rate of 2.5 ml/min (UV detection at 330 nm). GC Analysis was carried out on an *Agilent-6890N* gas chromatograph, using an *HP-5* capillary column (28 m×0.32 mm i.d.), an FID detector at 260°, and a column temp. of 180°, with N₂ carrier gas and flow rate of 40 ml/min. UV Spectra were recorded on a *Shimadzu* spectrometer; λ_{\max} (log ϵ) in nm. Optical rotations were determined on a *Perkin-Elmer 243B* digital polarimeter. IR Spectra were recorded on a *Nicolet Avatar-360* FT-IR spectrometer; in cm⁻¹. NMR Spectra were recorded in CD₃OD or (D₆)DMSO on a *Bruker AM-500* spectrometer; δ in ppm rel. to Me₄Si, *J* in Hz. FAB- and HR-ESI mass spectra were recorded on *KYKY-ZHP-5* and *Bruker APEX* mass spectrometers, resp.

Plant Material. The stems of *Cistanche salsa* were collected from Yanchi, Ningxia Hui Autonomous Region, China, in April. The plant was identified by Prof. *Peng-Fei Tu*, School of Pharmaceutical Sciences, Peking University. A voucher specimen was deposited at the Herbarium of the Peking University Modern Research Center for Traditional Chinese Medicine.

Extraction and Isolation. The dried stems of *C. salsa* (8.0 kg) were extracted with 75% aq. EtOH (80 l) at r.t. by percolation. The solvent was removed, the residue was suspended in H₂O (4 l), and extracted with petroleum ether (PE; 12 l), AcOEt (12 l), and BuOH (12 l) to afford, after solvent removal, 100 g of PE-, 99 g of AcOEt-, and 100 g of BuOH-soluble extract, resp. Part of the AcOEt-soluble extract (90 g) was subjected to CC (SiO₂; CHCl₃/MeOH 0:1 → 1:2) to afford 75 fractions (Fr.). Fr. 51–53 (6.0 g) were combined (=Fr. A) and rechromatographed (*Sephadex LH-20*; MeOH/H₂O 1:1) to afford eleven sub-fractions (Fr. A1–A11). Fr. A6 and Fr. A7 were combined (2.5 g; Fr. B) and resubjected to CC (*ODS*; MeOH/H₂O 1:9–5:5) to provide 35 further fractions (Fr. B1–B35). Fr. B16–B25 were combined (0.5 g; Fr. C) and rechromatographed (*Sephadex LH-20*; then prep. HPLC, MeCN/MeOH/H₂O 10:18:75) to provide tubuloside B [11] (55 mg). Fr. B26–B32 (0.35 g) were combined (0.35 g, Fr. D) and rechromatographed (*Sephadex LH-20*; 20% aq. MeOH) to yield seven fractions (Fr. D1–D7). Fr. D1 (70 mg) was purified by prep. HPLC (MeCN/MeOH/H₂O 10:26:72) to afford **2** (23 mg), **3** (8 mg), and cistanoside C [7] (12 mg). Fr. D3 (45 mg) was purified by prep. HPLC (MeCN/MeOH/H₂O 10:20:70) to provide **6** (22 mg). Fr. D4 (36 mg) was purified by prep. HPLC (MeCN/MeOH/H₂O 9:18:73) to provide **5** (20 mg). Fr. D5 (55 mg) was purified by prep. HPLC (MeCN/MeOH/H₂O 10:24:66) to afford **1** (28 mg). Fr. D7 (40 mg) was purified by prep. HPLC (MeCN/MeOH/H₂O 10:16:74) to provide **4** (18 mg). The original Fr. 54 and Fr. 55 were combined and purified by repeated CC (*Sephadex LH-20*) to afford acteoside [6] (0.1 g) and 2'-acetylacteoside (8.9 mg) [10]. Fr. 56–58 were combined and purified by repeated CC (*Sephadex LH-20* and *ODS*) to furnish isoacteoside (25 mg) [11] and cistanoside D (32 mg) [7]. Fr. 59–64 were combined and purified by repeated CC (*Sephadex LH-20*) and prep. HPLC (MeCN/MeOH/H₂O 10:15:84) to afford echinacoside (33 mg) [6].

Salsaside A (= *Benzyl 6-O-[(E)-3-(3,4-Dihydroxyphenyl)prop-2-enoyl]-3-O- α -L-rhamnopyranosyl- β -D-glucopyranoside*; **1**). Amorphous powder. UV (MeOH): 328 (3.50). $[\alpha]_{\text{D}}^{20} = -35.6$ ($c = 0.1$, MeOH). IR (KBr): 3421, 1690, 1628, 1605, 1520. ¹H- and ¹³C-NMR: see *Table 1*. FAB-MS: 577 ($[M - H]^-$). HR-ESI-MS: 596.2348 ($[M + \text{NH}_4]^+$, C₂₈H₃₈NO₁₃⁺; calc. 596.2343).

Salsaside B (= *Benzyl 4-O-[(E)-3-(3,4-Dihydroxyphenyl)prop-2-enoyl]-3-O- α -L-rhamnopyranosyl- β -D-glucopyranoside*; **2**). Amorphous powder. UV (MeOH): 332 (3.20). $[\alpha]_{\text{D}}^{20} = -35.6$ ($c = 0.1$, MeOH). IR (KBr): 3411, 1692, 1630, 1600, 1514. ¹H- and ¹³C-NMR: see *Table 1*. HR-ESI-MS: 596.2345 ($[M + \text{NH}_4]^+$, C₂₈H₃₈NO₁₃⁺; calc. 596.2343).

Salsaside C (= *4-O-[(E/Z)-3-(4-Hydroxyphenyl)prop-2-enoyl]-3-O- α -L-rhamnopyranosyl- β -D-glucopyranoside*; **3**). Amorphous powder. UV (MeOH): 315 (3.23), 225 (1.80). IR (KBr): 3432, 1689, 1628, 1609, 1519. ¹H- and ¹³C-NMR: see *Table 1*. HR-ESI-MS: 561.1958 ($[M - H]^-$, C₂₈H₃₃O₁₂⁻; calc. 561.1972).

Salsaside D (=2-(4-Hydroxyphenyl)ethyl 2-O-Acetyl-4-O-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-3-O- α -L-rhamnopyranosyl- β -D-glucopyranoside; **4**). Amorphous powder. UV (MeOH): 328 (3.40). $[\alpha]_D^{20} = -58.3$ ($c=0.1$, MeOH). IR (KBr): 3397, 1720, 1692, 1630, 1596, 1512. ^1H - and ^{13}C -NMR: see Table 2. FAB-MS: 649 ($[M-H]^-$), 443 ($[M-H-Ac-Caf]^-$). HR-ESI-MS: 668.2563 ($[M+NH_4]^+$, $\text{C}_{31}\text{H}_{42}\text{NO}_{15}^+$; calc. 668.2554).

Salsaside E (=2-(4-Hydroxy-3-methoxyphenyl)ethyl 2-O-Acetyl-4-O-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-3-O- α -L-rhamnopyranosyl- β -D-glucopyranoside; **5**). Amorphous powder. UV (MeOH): 330 (3.21). $[\alpha]_D^{20} = -33.3$ ($c=0.1$, MeOH). IR (KBr): 3370, 1721, 1690, 1630, 1600, 1514. ^1H - and ^{13}C -NMR: see Table 2. FAB-MS: 679 ($[M-H]^-$), 533 ($[M-H-Rha]^-$). HR-ESI-MS: 679.2228 ($[M-H]^-$, $\text{C}_{32}\text{H}_{39}\text{O}_{16}$; calc. 679.2238).

Salsaside F (=2-(3,4-Dihydroxyphenyl)ethyl 2-O-Acetyl-6-O-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-3-O- α -L-rhamnopyranosyl- β -D-glucopyranoside; **6**). Amorphous powder. UV (MeOH): 315 (3.28). $[\alpha]_D^{20} = -38.5$ ($c=0.1$, MeOH). IR (KBr): 3416, 1725, 1690, 1630, 1600, 1510. ^1H - and ^{13}C -NMR: see Table 2. FAB-MS: 649 ($[M-H]^-$). HR-ESI-MS: 668.2543 ($[M+NH_4]^+$, $\text{C}_{31}\text{H}_{42}\text{NO}_{15}^+$; calc. 668.2554).

Acid Hydrolysis and Determination of Absolute Sugar Configuration. The compound (3 mg) was placed in a sealed tube and hydrolyzed with 2N aq. CF_3COOH (5 ml) by heating on a water bath for 3 h [16]. After cooling down, the mixture was diluted with H_2O (15 ml), and extracted with CHCl_2 (3×5 ml). The aq. layer was repeatedly evaporated to dryness with MeOH, until neutral. The sugars were identified by co-TLC with authentic samples, eluting with $\text{BuOH}/\text{AcOH}/\text{H}_2\text{O}$ 4:2:1, and detected by spraying with anisaldehyde/ H_2SO_4 , followed by heating. The R_f values of glucose (Glc) and rhamnose (Rha) were 0.54 and 0.69, resp.

The abs. sugar configurations were determined as follows. To a soln. of the sugar residue in pyridine (60 μl), obtained from the hydrolysis, were added L-cysteine methyl ester hydrochloride and hexamethyl-disilazine/ Me_2SiCl 3:1. The mixture was stirred at 60° for 30 min. The resulting precipitate was removed by centrifugation, and the supernatant was concentrated and partitioned between hexane and H_2O . The org. layer was then analyzed by GC. By comparison with standard monosaccharides, D-Glc (t_R 12.45 min) and L-Rha (5.32 min) were identified for **1–6**.

REFERENCES

- [1] Pharmacopoeia Editing Committee, 'Chinese Pharmacopoeia', Chemical Industry Publisher, Beijing, 2000, Vol. 1, p. 103.
- [2] X-C. Geng, L-W. Song, X-P. Pu, P-F. Tu, *Biol. Pharm. Bull.* **2004**, 27, 797.
- [3] X-P. Pu, Z-H. Song, Y-Y. Li, P-F. Tu, H-N. Li, *Planta Med.* **2003**, 69, 65.
- [4] G-Q. Sheng, X-P. Pu, L. Lei, P-F. Tu, C-L. Li, *Planta Med.* **2002**, 68, 966.
- [5] H. Kobayashi, H. Karasawa, T. Miyase, S. Fukushima, *Chem. Pharm. Bull.* **1984**, 32, 1729.
- [6] H. Kobayashi, H. Karasawa, T. Miyase, S. Fukushima, *Chem. Pharm. Bull.* **1984**, 32, 3009.
- [7] H. Kobayashi, H. Karasawa, T. Miyase, S. Fukushima, *Chem. Pharm. Bull.* **1984**, 32, 3880.
- [8] H. Karasawa, H. Kobayashi, N. Takizawa, T. Miyase, S. Fukushima, *Yakugaku Zasshi* **1986**, 106, 721.
- [9] A. Moriya, P-F. Tu, D. Karasawa, H. Arima, T. Deyama, K. Kegasawa, *Nat. Med.* **1995**, 49, 383.
- [10] A. Moriya, P-F. Tu, D. Karasawa, H. Arima, T. Deyama, K. Hayashi, *Nat. Med.* **1995**, 49, 394.
- [11] H. Kobayashi, H. Oguchi, N. Takizawa, T. Miyase, A. Ueno, K. Usmanhani, M. Ahmad, *Chem. Pharm. Bull.* **1987**, 35, 3309.
- [12] N-D. Tommasi, L. Rastrelli, J. Cumanda, G. Speranza, C. Pizza, *Phytochemistry* **1996**, 42, 163.
- [13] T. Miyase, R. Yamamoto, A. Ueno, *Phytochemistry* **1996**, 43, 475.
- [14] Z-J. Jia, J-J. Gao, Z-M. Liu, *Indian J. Chem., Sect. B* **1994**, 33, 460.
- [15] F. Yoshizawa, T. Deyama, N. Takizawa, *Chem. Pharm. Bull.* **1990**, 38, 1927.
- [16] M. Haddad, T. Miyamoto, V. Laurens, M.-A. Lacaille-Dubois, *J. Nat. Prod.* **2003**, 66, 372.

Received June 8, 2006